AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04022291 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biocon Insulin 70/30
Description: Biocon Insulin 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.~Biocon insulin is produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing a non-pathogenic laboratory strain of Escherichia coli.
Study NCT01614405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF/FTC/LPV/r
Description: one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir 200mg for 6 months or less if adverse events occur
Study NCT01614405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 months therapy with blinded placebo followed by 6 months open label therapy with Kaletra and Truvada.
Study NCT01285999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROMUS Element Coronary Stent System
Description: Everolimus-eluting Coronary Stent Drug-eluting Stent (DES) implantation
Study NCT01285999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAXUS Liberté Coronary Stent System
Description: Paclitaxel-eluting Coronary Stent Drug-eluting Stent (DES) implantation
Study NCT03702777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8302
Description: Oral Capsule
Study NCT03702777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study NCT00772889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK2186877A
Description: One intramuscularly injection at Day 0
Study NCT00772889 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' Fluarix™
Description: One intramuscularly injection at Day 0
Study NCT03644589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg,Given intravenous (IV) infusion, every 21 days
Study NCT03644589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2, intravenous (IV) infusion, every 21 days, for 6 cycles Given IV
Study NCT03962010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control
Study NCT03962010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control
Study NCT02028494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Two dosages comparison
Study NCT02028494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Two dosages comparison
Study NCT02378792 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vagus Nerve Stimulation
Description: Vagus Nerve Stimulator
Study NCT02378792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation
Description: Vagus Nerve Stimulator
Study NCT01929798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: portable Artificial Pancreas
Description: The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels.
Study NCT02300688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: administration of 1 time administration of the test drug (Treatment A)
Study NCT02300688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: administration of 1 time administration of the reference drug (Treatment B)
Study NCT03118258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'Pap smear' arm
Description: Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by direct patient referral for Pap smear testing in a partner health facility.
Study NCT03118258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'Self-collected vaginal swab for HPV testing + pap smear triage' arm
Description: Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by patient referral for Pap smear testing in a partner health facility if the HPV-HR test is positive.~A women who tests negative for HPV-HR can still be referred for further Pap smear testing, or can be referred for a gynaecological consultation for any other reason.
Study NCT01906008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for 4 months beginning at chemotherapy initiation.
Study NCT01906008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo by mouth for the first day of chemotherapy, then 1 dose every 12 hours for 4 months beginning at chemotherapy initiation.
Study NCT01906008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit.
Study NCT01906008 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit.
Study NCT01906008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Test
Description: Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
Study NCT01906008 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sensory Test
Description: Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
Study NCT00740831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL4001
Description: tablets
Study NCT00740831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprorelin
Description: solution for injection
Study NCT01830972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA-ER 500 mg
Description: oral tablets
Study NCT01830972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA-IR 500 mg
Description: oral capsules
Study NCT02777801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: anti-HBV
Study NCT02777801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: anti-HBV
Study NCT01931124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Training
Study NCT01931124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Training
Study NCT03956732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Protein (high)
Description: High protein yoghurt which contains approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.
Study NCT03956732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: One daily tablet containing 20 μg of vitamin D3, cholecalciferol.
Study NCT03956732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk Protein (medium)
Description: Ordinary yoghurt containing approx. 3.3 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.
Study NCT03956732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Protein (medium)
Description: Ordinary yoghurt containing approx. 3.3 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.
Study NCT05549570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin/Metformin HCl 50/850 mg film-coated tablet
Description: The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/850 mg film-coated tablet
Study NCT03183076 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: modified adkins diet
Description: Patients were assigned to two groups, one of them received modified adkins diet for treatment of drug-resistant epilepsy. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis
Study NCT03183076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacotherapy without diet
Description: Patients were assigned to two groups, one of them received conventional treatment with antiepileptic drugs without a special diet
Study NCT02020330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine 3 days
Description: One tablet contains 20mg artemether and 120mg lumefantrine. The standard regimen is twice daily for 3 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 3 days arm.
Study NCT02020330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine 5 days
Description: One tablet contains 20mg artemether and 120mg lumefantrine. The experiment regimen is twice daily for 5 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 5 days arm.
Study NCT02408315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: misoprostol/placebo
Description: buccal or vaginal routes of administration/ placebo to compare methods for efficacy and safety during induction.
Study NCT04119882 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: New biomarker test
Study NCT03749070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Silymarin
Description: It is a randomized, double-blind, controlled clinical trial to be performed at outpatient level. The intervention will last 12 weeks and the invited participants will be patients attended at the outpatient clinic of the Edgard Santos Hospital, which will be randomized into two groups: control and intervention. Data on laboratory and clinical markers, imaging, nutritional and dietary assessment will be collected at the beginning and end of the trial for comparison purposes.
Study NCT03749070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Silymarin
Description: It is a randomized, double-blind, controlled clinical trial to be performed at outpatient level. The intervention will last 12 weeks and the invited participants will be patients attended at the outpatient clinic of the Edgard Santos Hospital, which will be randomized into two groups: control and intervention. Data on laboratory and clinical markers, imaging, nutritional and dietary assessment will be collected at the beginning and end of the trial for comparison purposes.
Study NCT01421108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Framing (Gain-framed messages)
Description: The adolescents will randomly assign to three groups: gain-framed message and loss- framed message. Each group of adolescents will read the respective pamphlets with the exception of the control group. The gain-framed pamphlet contains six positive messages with three related full-color images(6.1 X 4.5). The gain-framed pamphlet, entitled The Benefits of good oral hygiene, emphasizes the benefits of brushing, and flossing.
Study NCT01421108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Framing (Loss-framed messages)
Description: The adolescents will randomly assign to three groups: gain-framed message , loss- framed message and a control group. Each group of adolescents will read the respective pamphlets with the exception of the control group.~The loss-framed pamphlet contains six negative messages with three related full-color images (6.1 X 4.5). The loss-framed pamphlet, entitled The disadvantages of poor oral hygiene, emphasizes the costs of not brushing and flossing.
Study NCT01053416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yag laser iridotomy
Description: the procedure will be performed by using a Yag laser. Single spot, 1 mJ power, beam aimed to an existing iris crypt
Study NCT01428544 — intervention group
Intervention type: DRUG
Intervention: Fondaparinux sodium
Description: For patients whose body weight is 100 kg or more, fondaparinux is injected 10 mg subcutaneously once daily for treatment of acute pulmonary thromboembolism or acute deep venous thrombosis.
Study NCT00888368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transpatellar Approach
Description: The transpateller approach for the injection of the dye will be used.
Study NCT01662986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium bromide
Description: 18 mcg once a day (QD)
Study NCT01662986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once a day (QD)
Study NCT02515851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Study NCT00888368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprapatellar
Description: The suprapatellar approach will be used for the injection of the dye.
Study NCT03907358 — intervention group
Intervention type: PROCEDURE
Intervention: phacoemulsification
Study NCT02596308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plague vaccine
Description: Plague vaccine is comrised by native fraction 1 capsule (F1) and recombine virulence-associated (V) antigens.
Study NCT04943094 — intervention group
Intervention type: OTHER
Intervention: Urodynamic examination
Description: A urodynamic examination is performed in all patients four to six weeks following TURBT and repeated six months later in order to obtain bladder function and possible changes.
Study NCT00673465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 497079
Description: SCH 497079 100 mg capsule, administered orally, once daily for 4 weeks
Study NCT00673465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules matching SCH 497079, administered orally, once daily for 4 weeks
Study NCT00673465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin extended release 750 mg, 2 tablets administered orally, once daily for 4 weeks (1500 mg total daily dose)
Study NCT02515851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02516891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents implantation in bifurcation lesions
Study NCT01614366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AM 5 + DM 0
Description: Amlodipine 5 mg + DMTA07 0mg, once daily
Study NCT01614366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM 5 + DM 0
Description: Amlodipine 5 mg + DMTA07 0mg, once daily
Study NCT01614366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM 5 + DM 2.5
Description: Amlodipine 5 mg + DMTA07 2.5mg, once daily
Study NCT01614366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM 5 + DM 7.5
Description: Amlodipine 5 mg + DMTA07 7.5mg, once daily
Study NCT01614366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM 5 + DM 30
Description: Amlodipine 5 mg + DMTA07 30mg, once daily
Study NCT03908866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PICC(Peripherally inserted central catheter)
Description: The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.
Study NCT03908866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CVC(Central venous catheter )
Description: The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, using the Seldinger technique. A suitable sterile field will be established.
Study NCT02980263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Study NCT01935674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch ritonavir-boosted PI
Description: Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.
Study NCT01935674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continue Ritonavir-boosted PI+Rosuvastatin
Description: Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).
Study NCT03160066 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Rhamnosus (JB-1)
Description: Lactobacillus Rhamnosus (JB-1) capsule
Study NCT03160066 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03710291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC101
Description: Oral, non-absorbed, polymeric hydrochloric acid binder
Study NCT03710291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT04323917 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid biopsy
Description: Detection and quantification of EMT-transcription factor mRNA levels in blood
Study NCT04247828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental AAC
Description: Participant receives an AAC system comprising a single hybrid wearable sensor for head-mediated cursor control that is integrated with an adaptive and individualized keyboard to test communication performance.
Study NCT04247828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Generic AAC
Description: Participant receives an AAC system comprising a single hybrid wearable sensor for head-mediated cursor control that is integrated with a generic QWERTY keyboard to test communication performance.
Study NCT04555811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT596
Description: FT596 is given 2-3 days after rituximab; however, it may be delayed for up to 7 days until all rituximab infusion related toxicities resolve to ≤Grade 1.
Study NCT02905552 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT03568994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone
Description: Patients will receive standard of care MRC based Induction chemotherapy (such as ADE 10+3+5 with daily atovaquone dosing starting on day 6. In order to accommodate potential drug shortages modifications to ADE 10+3+5 that retain the MRC based induction backbone regimen of DA are allowed (see second Arm). These include but are not limited to substitution of etopophos for etoposide, exclusion of etoposide, use of CPX-351 (VYXEOS (daunorubicin and cytarabine) liposome) only, and daunorubicin and cytarabine (DA) + gemtuzumab ozogamicin (GO).~Patients will be monitored for adherence to and tolerance of daily dosing of atovaquone. Peripheral blood (PB) and bone marrow plasma samples will be obtained to measure atovaquone concentrations.
Study NCT03568994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: As part of routine Induction 1 chemotherapy (ADE 10+3+5)
Study NCT03568994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: As part of routine Induction 1 chemotherapy (ADE 10+3+5)
Study NCT03568994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: As part of routine Induction 1 chemotherapy (ADE 10+3+5)
Study NCT03568994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: As part of routine Induction 1 chemotherapy(DA 3+10 + GO)
Study NCT04555811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 is administered as an IV infusion per institutional standard of care and package insert on 2-3 days (48 to 72 hours) prior to the FT596 infusion
Study NCT01782612 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal analgesic techniques
Description: Postoperative pain was controlled for all patients routinely by intravenous sulfentanil patient-controlled analgesia (PICA) in combination with Parecoxib(40 mg, every 12 h). PICA was continued with sulfentanil (1.25 µg.h-1) and 1.25 µg sulfentanil bolus with a 8-min lockout time. Oral oxycodone 0.2 mg was administered necessarily.
Study NCT01782612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multimodal analgesic techniques
Description: Postoperative pain was controlled for all patients routinely by intravenous sulfentanil patient-controlled analgesia (PICA) in combination with Parecoxib(40 mg, every 12 h). PICA was continued with sulfentanil (1.25 µg.h-1) and 1.25 µg sulfentanil bolus with a 8-min lockout time. Oral oxycodone 0.2 mg was administered necessarily.
Study NCT01885026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eScreen
Description: Access to the eScreen platform offering assessment of alcohol and drug use, with automated feedback on problematic or non-problematic use. Follow-up over time based on user needs.
Study NCT01782612 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total uni-Hip Replacement
Description: All subjects will undergo standard Total uni-Hip Replacement